Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme

@article{Dequeker2011MutationAO,
  title={Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme},
  author={Elisabeth M. C. Dequeker and Marjolijn J. L. Ligtenberg and Sara Vander Borght and Johan H. J. M. van Krieken},
  journal={Virchows Archiv},
  year={2011},
  volume={459},
  pages={155-160}
}
In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS (KRAS) wild-type colorectal tumors. Information on the KRAS status of the patients tumor is thus key for clinical practice; however, there is little guidance or definition on which KRAS mutations to assess and how to assess them. To ensure the consistency and the quality of KRAS test results in Europe, an interlaboratory control network needs to be set up. This pilot study aimed to identify the variables that… CONTINUE READING